SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Robert A. Hauser, Mark Forrest Gordon, Yoshikuni Mizuno, Werner Poewe, Paolo Barone, Anthony H. Schapira, Olivier Rascol, Catherine Debieuvre, Mandy Fräßdorf, Minimal Clinically Important Difference in Parkinson’s Disease as Assessed in Pivotal Trials of Pramipexole Extended Release, Parkinson's Disease, 2014, 2014, 1

    CrossRef

  2. 2
    Robert A. Hauser, Dee Silver, Azhar Choudhry, Eli Eyal, Stuart Isaacson, Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease, Movement Disorders, 2014, 29, 8
  3. 3
    A. H. V. Schapira, P. Barone, R. A. Hauser, Y. Mizuno, O. Rascol, M. Busse, C. Debieuvre, M. Fraessdorf, W. Poewe, Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  4. 4
    Anthony E. Lang, Eldad Melamed, Werner Poewe, Olivier Rascol, Trial designs used to study neuroprotective therapy in Parkinson's disease, Movement Disorders, 2013, 28, 1
  5. 5
    Robert A. Hauser, Peggy Auinger, Determination of minimal clinically important change in early and advanced Parkinson's disease, Movement Disorders, 2011, 26, 5
  6. 6
    Dee E. Silver, Philip O. Buck, Determining the Efficacy of Rasagiline in Reducing Bradykinesia Among Parkinson's Disease Patients: A Review, International Journal of Neuroscience, 2011, 121, 9, 485

    CrossRef

  7. 7
    C. Warren Olanow, Kathryn B. Wunderle, Karl Kieburtz, Milestones in movement disorders clinical trials: Advances and landmark studies, Movement Disorders, 2011, 26, 6
  8. 8
    Carl E. Clarke, Smitaa Patel, Natalie Ives, Caroline Rick, Keith Wheatley, Richard Gray, Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?, Movement Disorders, 2011, 26, 7
  9. 9
    Olivier Rascol, Paolo Barone, Robert A. Hauser, Yoshikuni Mizuno, Werner Poewe, Anthony H.V. Schapira, Laurence Salin, Mandy Sohr, Catherine Debieuvre, Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease, Movement Disorders, 2010, 25, 14
  10. 10
    Robert A. Hauser, Kelly E. Lyons, Reply: Intravenous glutathione in Parkinson's disease, Movement Disorders, 2010, 25, 7
  11. 11
    R. Talati, W. L. Baker, A. A. Patel, K. Reinhart, C. I. Coleman, Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson’s disease: a meta analysis, International Journal of Clinical Practice, 2009, 63, 4
  12. 12
    Ripple Talati, Kurt Reinhart, William Baker, C. Michael White, Craig I. Coleman, Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors, Parkinsonism & Related Disorders, 2009, 15, 7, 500

    CrossRef

  13. 13
    Pablo Martinez-Martin, Günther Deuschl, Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease, Movement Disorders, 2007, 22, 6